MILWAUKEE, April  07, 2026  (GLOBE NEWSWIRE) -- Ademi LLP is investigating Terns (NASDAQ:TERN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.   

TERN

Shareholder Alert: Ademi LLP investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

Investigation into TERN's Merck Transaction Raises Concerns

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>MILWAUKEE, April  07, 2026  (GLOBE NEWSWIRE) -- Ademi LLP is investigating Terns (NASDAQ:TERN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Ademi LLP is investigating TERN for potential breaches of fiduciary duty related to its transaction with Merck, offering $53 per share, which imposes penalties for competing bids. This scrutiny may threaten shareholder confidence and lead to potential legal challenges against TERN’s board.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Ademi LLP investigates TERN for potential fiduciary duty breaches.</li><li>TERN&#039;s deal with Merck offers $53 per share to stockholders.</li><li>The transaction limits competing bids, imposing penalties.</li><li>Shareholders may question the board&#039;s fiduciary responsibilities.</li><li>Class-action lawsuits could arise from this investigation.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Merck &amp; Co (MRK)</strong>: Merck&#039;s merger with TERN is under scrutiny, posing risks to completion.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This situation falls into Corporate Developments due to potential legal actions and investigations affecting TERN’s governance and share value amidst its intended M&amp;A with Merck.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Ademi LLP&#039;s investigation could lead to declines in TERN’s stock price.</li><li>Legal challenges may delay TERN&#039;s merger with Merck, impacting investor sentiment.</li><li>Shareholder dissatisfaction could prompt a review of TERN&#039;s governance practices.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>TERN&#039;s shareholders to receive $53.00 per share in the Merck deal.</li><li>Transaction values TERN at approximately $6.7 billion.</li><li>Penalties exist for TERN accepting competing offers.</li><li>Ademi LLP focuses on shareholder rights and fiduciary duty breaches.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>TERN may face downward pressure in the near term due to legal uncertainties.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>MILWAUKEE, April  07, 2026  (GLOBE NEWSWIRE) -- Ademi LLP is investigating Terns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TERN">TERN</a>) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.</p>    <p>Click <a href="https://www.globenewswire.com/Tracker?data=rnO3MNxjYZZtToKSM32i7F8hA93FxMQp78SPNxDZTuvPJ1E3e6lQin0g-awREUD8fqUrLJtNWxtNVb5U0PkUSbRZPu4GC9sQNoymVgvks2dx1qE-swevwgBViaeIzryI" rel="nofollow" target="_blank">here</a> to learn how to join our investigation and obtain additional information or contact us at <a href="https://www.globenewswire.com/Tracker?data=Yb-cBoAUoiRhMPDk_6x9-R00zWgwErTjJHV29P7xhJl9aZFA5jzVg6EwaWOipgsgWb7DBaHu_JDO8vv1-Ktfn7tcRFiGCNlE-w_qtOaPXD8=" rel="nofollow" target="_blank">gademi@ademilaw.com</a> or toll-free: 866-264-3995. There is no cost or obligation to you.</p>    <p>In the transaction, Terns stockholders will receive $53.00 per share in cash, representing an equity value of approximately $6.7 billion or $5.7 billion net of acquired cash. Terns insiders will receive substantial benefits as part of change of control arrangements.</p>    <p>The transaction agreement unreasonably limits competing transactions for Terns by imposing a significant penalty if Terns accepts a competing bid. We are investigating the conduct of the Terns board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.</p>    <p>We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.</p>    <p>Contacts</p>    <p>Ademi LLP                <br></br>Guri Ademi<br></br>Toll Free: (866) 264-3995<br></br>Fax: (414) 482-8001</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4NTIwMyM3NTIyNzk1IzIwMTc2NDI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MzU5ZWRhNTAtNmVkOC00OTI5LTkwMGUtZjc2ZGZlYjkzNjFmLTEwMjkyMTUtMjAyNi0wNC0wNy1lbg==/tiny/Ademi-LLP.png" referrerpolicy="no-referrer-when-downgrade"></img>

Ademi LLP is investigating TERN for potential breaches of fiduciary duty related to its transaction with Merck, offering $53 per share, which imposes penalties for competing bids. This scrutiny may threaten shareholder confidence and lead to potential legal challenges against TERN’s board.

Shareholder Alert: Ademi LLP investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News